Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

iShares MSCI Germany (DAX)Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Germany (DAX) trades at $40.84 (market cap $1.42B), while Regeneron Pharmaceuticals Inc trades at $750.8 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 53.6× iShares MSCI Germany (DAX)'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

EWGREGN
Market Cap
$1.42B$76.14B
Volume
1,110,573500,239
Sector
Broad Market / FactorHealth
52-Week High
$44.59$852.03
52-Week Low
$38.08$557.73
Typical Hold Time
56 Days107 Days
Enterprise Value
—$70.85B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.

Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWG

No sentiment data available yet.

REGN
98% Buy2% Sell
Avg holding period · 107 Days

Top news

Latest headlines on both assets

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →